FDA approves Zepbound for obstructive sleep apnea - Becker's Hospital Review
Zepbound, Eli Lilly's weight loss medication, became the first FDA-approved drug for obstructive sleep apnea on Dec. 20. Trials showed clinically meaningful reductions in apnea events and higher remission rates for mild obstructive sleep apnea compared to placebo. The approval is expected to influence payer coverage of GLP-1 drugs and impact the CPAP machine market.
Highlighted Terms
Related News
FDA approves Zepbound for obstructive sleep apnea - Becker's Hospital Review
Zepbound, Eli Lilly's weight loss medication, became the first FDA-approved drug for obstructive sleep apnea on Dec. 20. Trials showed clinically meaningful reductions in apnea events and higher remission rates for mild obstructive sleep apnea compared to placebo. The approval is expected to influence payer coverage of GLP-1 drugs and impact the CPAP machine market.